However, the approaches of targeting vimentin have yielded little success in treating tumors, probably because all the previous attempts focused on finding vimentin inhibitors that can directly kill cancer cells but ignored the fact that the depletion of vimentin itself does not result in the death of normal cells (Colucci-Guyon et al., 1994) or cancer cells, except under extreme non-physiological conditions or special circumstances where synthetic lethal may occur (Bollong et al., 2017). Here, VIM is linked to cancer.